Full text
| |
| Author(s): |
Paulo Vitor Soeiro Pereira
Total Authors: 1
|
| Document type: | Doctoral Thesis |
| Press: | São Paulo. |
| Institution: | Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB/SDI) |
| Defense date: | 2012-12-06 |
| Examining board members: |
Antonio Condino Neto;
Vera Lucia Garcia Calich;
Ana Campa;
Beatriz Tavares Costa Carvalho;
Marcelo de Franco
|
| Advisor: | Antonio Condino Neto |
| Abstract | |
We investigated the soluble guanylate cyclase agonist, BAY 41-2272, as an alternative to compensate for failures in of monocytes function. We evaluated the in vitro effect of the drug on human cells lines and peripheral blood cells. The BAY increased expression of CD11b, CD18, CD14, TLR4, TLR2 and CD163 and induce the production of TNF-<font face=\"Symbol\">a, IL-1<font face=\"Symbol\">b, IL-6 and IL-12p70 in THP-1 cells and monocytes. Furthermore, the drug increased NADPH oxidase gene (CYBB, CYBA and NCF2) and protein (gp91phox and p67phox) expression. Also, BAY activates the PKG-dependent NF-kB pathway (p65). More importantly, the drug increased microbicidal activity against S. aureus and C. albicans of monocytes from patients with CGD and MPO deficiency. In animals, BAY 41-2272 induced intense influx of macrophages to the peritoneum and inflammation. BAY potentiated the spreading, phagocytic activity, microbicidal activity, spontaneous production of nitric oxide and PMA-induced hydrogen peroxide release by peritoneal macrophages, increasing host protection against C. albicans. Taken together, our results confirm the potential of BAY 41-2272, or its pathway (sGC / PKG), as an alternative for the development of therapies against infections. (AU) | |